THCV
Δ9-tetrahydrocannabivarin
Viewing r1 — May 11, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
THCV (tetrahydrocannabivarin) is a naturally-occurring cannabinoid of the phytocannabinoid class. It is the propyl homolog of Δ9-THC, distinguished by opposing receptor activity at typical doses. THCV is a CB1 neutral antagonist at low-to-moderate doses, producing its effects by blocking endocannabinoid signaling rather than activating it.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Isolated from cannabis tincture in 1970 by Gill and colleagues, THCV remained pharmacologically uncharacterized for over three decades.[2] GW Pharmaceuticals advanced it to Phase 2 clinical trials for type 2 diabetes, producing the only published randomized controlled trial in humans.[3] No Phase 3 trials have been initiated, and THCV circulates primarily as a minor constituent of cannabis products and in isolated supplement form.
Subjective effects include appetite suppression, cognitive clarity, and absence of THC-like euphoria or intoxication. At clinical doses the experience is defined by subtraction — the hunger, sedation, and cognitive disruption characteristic of THC are absent, replaced by a neutral, clear-headed state that reads more as correction than alteration. At higher doses where CB1 agonism may emerge, THC-like psychoactive effects are theoretically possible but uncharacterized in humans.
THCV shows no abuse liability at clinical doses and no established toxic dose in any species.[4] The primary uncertainty is dose-dependent: THCV transitions from CB1 antagonism to partial agonism at higher concentrations, and the threshold for this switch in humans is unknown — meaning high-dose effects cannot be predicted from existing data.[1] A single 13-week clinical trial and limited preclinical work constitute the entire evidence base.[3]
History[edit]
Discovery
THCV was first isolated in 1970 from a cannabis tincture derived from Pakistani-grown Cannabis sativa by Gill and colleagues in the United Kingdom.[2] The compound was formally named tetrahydrocannabivarin by Merkus in 1971, establishing the "varin" suffix for propyl-chain cannabinoids.[2] For three decades following its isolation, THCV attracted almost no pharmacological attention, overshadowed entirely by Δ9-THC and cannabidiol.
Pharmacological characterization
The first systematic study of THCV's receptor activity came from Roger Pertwee's group at the University of Aberdeen, with Thomas et al. publishing quantified CB1 and CB2 binding data in 2005.[5] Pertwee's 2007 review in the British Journal of Pharmacology[1] — now cited over 1,800 times — established THCV as a pharmacologically distinct cannabinoid meriting independent investigation alongside THC and CBD.
Clinical development
GW Pharmaceuticals pursued THCV under the development code GWP42004 for type 2 diabetes, conducting the only published randomized controlled trial — a 13-week Phase 2 study in 62 patients published by Jadoon et al. in 2016.[3] The company was acquired by Jazz Pharmaceuticals in 2021, and no Phase 3 trials have been initiated as of 2026. Smith (2025) published data from an early Phase 1 trial evaluating THCV mucoadhesive strips for metabolic syndrome.[6]
The "varin" suffix in THCV's name denotes its membership in the propyl homolog series of cannabinoids — a naming convention established by Merkus in 1971 that extends to cannabidivarin (CBDV) and cannabigerovarin (CBGV). THCV is most abundant in narrow-leaf drug chemovars from South Africa, Afghanistan, and Pakistan, and has gained recent consumer attention as "diet weed" — a label reflecting its appetite-suppressing properties, though clinical evidence for weight loss remains absent.
Chemistry[edit]
Structural class
THCV belongs to the phytocannabinoid family — terpenophenolic compounds produced by Cannabis sativa — and is the propyl homologue of Δ9-THC. Where THC carries a five-carbon (pentyl) alkyl side chain at the C-3 position of its resorcinol ring, THCV carries a three-carbon (propyl) chain.[1] This two-carbon truncation is the single structural difference responsible for THCV's divergent pharmacology.
Other propyl-series cannabinoids — cannabidivarin (CBDV) and cannabigerovarin (CBGV) — share the same biosynthetic origin from a propyl precursor.[7]
Molecular identity
| Molecular formula | C₁₉H₂₆O₂ |
| Molecular weight | 286.4 g/mol |
THCV shares the dibenzopyran ring system common to classical cannabinoids: a benzene ring fused to a pyran ring via a cyclohexene bridge. The phenolic hydroxyl at C-1 is essential for cannabinoid receptor binding.[8]
Stereochemistry
THCV has two chirality centers at C-6a and C-10a. The naturally occurring form is (−)-trans-Δ9-THCV with (6aR,10aR) absolute configuration, directly analogous to natural Δ9-THC. Synthetic racemic mixture THCV and the Δ8-THCV isomer — which shifts the double bond from C-9/C-10a to C-8/C-9 — have been prepared for pharmacological study.[9]
Biosynthesis and natural occurrence
THCV is a minor constituent of Cannabis sativa, found at highest concentrations in narrow-leaf drug chemovars from South Africa, Afghanistan, and Pakistan.[10] Its biosynthesis follows a propyl-specific pathway: divarinolic acid condenses with geranyl pyrophosphate to form cannabigerovarinic acid (CBGVA), which is cyclized to tetrahydrocannabivarinic acid (THCVA) and then decarboxylated by heat to yield THCV.[11][12]
THCV is highly lipophilic with limited water solubility, consistent with the cannabinoid class.[13] Specific melting point and solubility values have not been published.
Pharmacology[edit]
Mechanism of action
THCV's defining pharmacological feature is a dose-dependent switch at the CB1. At low-to-moderate concentrations, it acts as a neutral antagonist — blocking CB1 signaling without suppressing the receptor's baseline activity.[5][14][1] This distinguishes THCV from the inverse agonist rimonabant, which actively suppressed constitutive CB1 signaling and was withdrawn due to depression and suicidality.[4][15]
At higher doses (above approximately 5 mg/kg intraperitoneally in mice), THCV transitions to CB1 partial agonism, producing THC-like effects including sedation, reduced movement, and lowered body temperature.[9][1] The dose at which this switch occurs in humans has not been established.
At CB2 receptors, THCV functions consistently as a partial agonist.[1][4] This CB2 activation mediates anti-inflammatory effects, suppressing nitric oxide production in immune cells and downregulating inflammatory proteins including iNOS, COX-2, and IL-1β.[16] In mouse models, combined CB2 agonism and CB1 blockade reduces inflammatory swelling and pain.[17]
Beyond cannabinoid receptors, THCV activates several TRP ion channels (TRPV1, TRPV2, TRPV3, TRPA1) and antagonizes TRPM8.[18][19] It also enhances 5-HT₁A serotonin receptor activation, producing antipsychotic-like effects in animal models.[20] Evidence for PPAR-γ modulation has been reported.[21][22]
THCV exhibits different signaling profiles depending on whether CB1 is expressed alone or in CB1-CB2 complexes, producing distinct downstream effects in each configuration.[23]
Pharmacokinetics
No controlled human pharmacokinetic data for Δ9-THCV have been published. The Jadoon et al. clinical trial administered 5 mg/day orally for 13 weeks but did not include pharmacokinetic evaluation.[3]
The most informative human data come from a study of the closely related Δ8-THCV isomer given orally to healthy participants.[24] Peak plasma levels occurred 3.8–5.0 hours after dosing, with dose-proportional increases in blood levels. Notably, Δ9-THCV appeared in plasma despite being absent from the formulation, suggesting metabolic interconversion between isomers.
Like Δ9-THC, THCV is expected to undergo liver metabolism and accumulate in fat tissue due to its high lipophilicity. The primary metabolite characterized for the Δ8-THCV structural analog is 11-OH-Δ8-THCV.[25] Human oral bioavailability, half-life, and clearance remain uncharacterized — a significant gap for clinical dose optimization.safety citation needed
Neuroscience[edit]
Where it acts
The only published human neuroimaging data come from Rzepa et al., who found that THCV reduced connectivity within the default mode network while increasing connectivity within the executive control network.[15] This dual pattern — quieter self-referential processing, sharper top-down cognitive control — is the opposite of the neural signature THC produces and may explain THCV's lack of intoxicating effects at clinical doses.
As a CB1 antagonist, THCV blocks the endocannabinoid system's retrograde signaling — the mechanism by which postsynaptic neurons normally suppress neurotransmitter release from presynaptic terminals. Blocking this pathway disinhibits neurotransmitter release, effectively increasing both excitatory and inhibitory transmission depending on the circuit. This mechanism is relevant to THCV's anticonvulsant properties: it suppresses seizure-like activity in brain slices and reduces seizure severity in rats.[26]
Why it matters
THCV engages the concept of endocannabinoid tone — the baseline level of endocannabinoid signaling that regulates mood, appetite, pain, and neuroplasticity. As a neutral antagonist, THCV may blunt phasic endocannabinoid surges (such as appetite responses to food cues) while preserving tonic signaling that maintains emotional stability.[4] This selectivity is the proposed explanation for why THCV avoids the depressogenic effects of rimonabant.
In Parkinson's disease models, THCV shows neuroprotective effects through dual action: CB1 antagonism reduces aberrant motor circuit plasticity while CB2 agonism provides anti-inflammatory and antioxidant protection.[27][28]
The dose at which THCV switches from CB1 antagonism to partial agonism in humans is unknown — animal data place the threshold at approximately 5 mg/kg in mice,[9] but scaling to humans is unreliable for lipophilic brain-active compounds. Whether THCV influences neuroplasticity markers has not been investigated.
Subjective Effects[edit]
THCV at clinical doses is an experience defined by subtraction. Where Δ9-THC adds — euphoria, appetite, altered time perception, cognitive haze — THCV at low-to-moderate doses removes these effects by blocking the same receptor THC activates. The result is not a high but a correction: reduced appetite drive, maintained cognitive clarity, and an unremarkable baseline that most users would not identify as psychoactive. Whether higher doses produce THC-like effects in humans is unknown, making the dose-response shape above clinical levels entirely uncharacterized.
Among cannabinoids, THCV sits at the opposite pole from THC. Its closest functional comparator is not another cannabinoid but the withdrawn pharmaceutical rimonabant — with the critical distinction that THCV's neutral antagonism avoids the mood disruption that ended rimonabant's clinical use.[4]
Effect Grid
At 5 mg/day oral — the only human-tested dose — THCV is non-psychoactive. No euphoria, perceptual changes, cognitive alteration, or mood shifts were reported in the 13-week Jadoon 2016 RCT. The subjective experience at this dose is defined by absence rather than presence of effects: no THC-like intoxication, no appetite stimulation, no sedation.
Physically, measurable metabolic changes occur without subjective awareness: reduced fasting plasma glucose, improved β-cell function, raised HDL-cholesterol, and reduced apolipoprotein B. Appetite suppression is documented in animal models and fMRI data but was not reported as a subjective experience by trial participants.
This dose is a therapeutic/metabolic dose, not a psychoactive one. Standard dose-tier framing — which assumes subjective effects — does not straightforwardly apply to THCV at its only characterized human dose.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Body high · Dizziness
Timeline
Pharmacological activity begins as THCV is absorbed orally. At the only clinically tested dose (5 mg/day), no subjective onset is perceived — effects are metabolic rather than experiential. Δ8-THCV Tmax is 3.
Peak plasma concentration reached approximately 4–5 hours post-dose based on Δ8-THCV PK data. At therapeutic doses, no subjective peak occurs — metabolic effects (glucose lowering, β-cell improvement) are measurable but not felt.
Residual pharmacological activity as THCV is cleared hepatically. Terminal half-life not determined in humans. Metabolic effects may persist beyond plasma clearance due to adipose tissue sequestration.
Safety[edit]
- Acute toxicity
- Negligible
- Chronic toxicity
- Negligible
- Withdrawal
- None
- Tolerance buildup
- none
- Tolerance reset
- —
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- Δ9-THC
Toxicity
No lethal dose has been established for THCV in any species.safety citation needed The most rigorous human safety data come from the Jadoon et al. Phase 2 trial, in which 62 patients received 5 mg/day orally for 13 weeks with no serious adverse events.[3] Smith (2025) similarly reported no serious adverse events with THCV mucoadhesive strips.[6] No published case reports of THCV-specific adverse events, overdose, or serious harm exist.
Organ toxicity
No organ toxicity studies have been published for THCV. The related Δ8-THCV isomer was hepatoprotective — not hepatotoxic — in a mouse liver injury model, acting through CB2-mediated anti-inflammatory mechanisms.[25]
Psychiatric safety
The central safety question for any CB1 antagonist is psychiatric risk, given that rimonabant was withdrawn due to depression and suicidality. Multiple lines of evidence indicate THCV does not share this risk at clinical doses: it is a neutral antagonist rather than an inverse agonist, no psychiatric adverse events occurred in the Jadoon trial, and neuroimaging shows a brain activity profile distinct from rimonabant.[3][15][4]
safety citation needed At higher doses where CB1 agonism emerges, THC-like adverse effects (anxiety, paranoia, cognitive impairment) could theoretically occur but have not been characterized in humans.
Psychological risks
No psychological adverse events have been reported in the published clinical literature. At 5 mg/day oral dosing, THCV was non-psychoactive and produced no mood disturbance, anxiety, or cognitive impairment.[3]
At doses sufficient to produce CB1 partial agonism, psychoactive effects similar to THC — including anxiety, paranoia, and transient cognitive impairment — would be expected.safety citation needed The 5-HT₁A agonism demonstrated by Cascio et al. may offer some protection against psychotomimetic effects, though this has not been confirmed in humans.[20]
Tolerance & dependence
No studies have investigated tolerance or abuse liability for THCV.safety citation needed As a CB1 neutral antagonist at typical doses, THCV would not be expected to produce the receptor changes that underlie THC tolerance. It also lacks the reward-circuit activation that drives cannabis dependence with high-THC products.[4]
At higher doses where CB1 partial agonism emerges, tolerance could theoretically develop through mechanisms analogous to THC. No withdrawal characterization data exist.
Drug interactions
No published drug interaction studies specifically for THCV exist.safety citation needed
CB1 agonist interactions
As a CB1 antagonist, THCV may reduce the psychoactive and therapeutic effects of Δ9-THC and other CB1 agonists when taken together.[5][9] In cannabis products with high THCV content, this interaction may alter the character of THC intoxication.
Liver enzyme interactions
THCV is expected to be processed by the same liver enzymes as THC (CYP2C9 and CYP3A4).inferred Drugs that inhibit these enzymes (azole antifungals, macrolide antibiotics, certain SSRIs, grapefruit juice) could increase THCV levels; drugs that induce them (rifampicin, carbamazepine, St. John's wort) could reduce them.
safety citation needed Co-administration with drugs that have narrow safety margins and are processed by the same enzymes (warfarin, phenytoin, certain statins) warrants caution.
Blood sugar-lowering drug interactions
The Jadoon trial used THCV alongside metformin with favorable results.[3] Combination with insulin or sulfonylureas could theoretically increase the risk of dangerously low blood sugar through additive glucose-lowering effects.
Contraindications
No substance-specific contraindication data exist for THCV. The following are inferred from its pharmacological profile:
Pregnancy and lactation: No reproductive safety data exist. Contraindicated based on general cannabinoid class principles.inferred
History of psychotic illness: At low doses, THCV's 5-HT1A activity may be antipsychotic.[20] At high doses where CB1 agonism emerges, psychotomimetic risk increases. The biphasic dose-response complicates risk assessment for this population.
Liver impairment: Impaired liver function could alter THCV processing and exposure given expected CYP2C9/CYP3A4 metabolism.inferred
Concurrent use of narrow-margin CYP2C9/CYP3A4 substrates: Relative contraindication based on uncharacterized interaction potential.inferred
Harm Reduction[edit]
Forms & Identification
THCV products have entered the consumer market as isolates, tinctures, vape cartridges, and edibles — often marketed with appetite-suppression or "energizing" claims. Because THCV is a minor cannabinoid present at low concentrations in most cannabis, products labeled as "THCV" rely on either selective extraction from high-THCV chemovars or synthetic production. Neither process is standardized across manufacturers.
The practical concern is label accuracy. Third-party certificate-of-analysis (COA) testing is the only reliable way to confirm that a THCV product contains what it claims. Products without accessible, batch-matched COAs should be treated as unverified. Cross-contamination with THC is a particular risk for users seeking non-psychoactive effects.
Guidelines
- Verify product contents through third-party COA testing before use. Confirm THCV concentration and check for THC contamination.
- Begin with low doses and increase gradually. The dose at which THCV shifts from CB1 antagonism to partial agonism in humans is unknown.
- If using THCV alongside THC-containing cannabis, be aware that THCV may alter the character of THC intoxication by blocking CB1 receptors.
- If managing blood sugar with medication, monitor glucose levels when adding THCV, as additive glucose-lowering effects are possible.
- Do not assume that "natural" or "hemp-derived" labeling guarantees non-psychoactive content — product quality varies widely.
Set & Setting
At clinical doses (5 mg/day oral), THCV is non-psychoactive and does not require the environmental precautions associated with psychoactive cannabinoids. No specific set-and-setting considerations apply at these doses.
At higher doses where CB1 partial agonism may emerge, the experience could shift toward THC-like psychoactivity. Because the threshold for this transition is unknown, users experimenting above clinical dosing ranges should apply the same environmental precautions as for THC: a familiar, comfortable setting, no driving or operating machinery, and the availability of a trusted companion.
Aftercare & integration. At clinical doses, THCV does not produce altered states requiring formal integration. Users taking THCV for metabolic or appetite-related purposes should track effects over days to weeks, as the compound's clinical benefits (glucose regulation, appetite modulation) emerge gradually rather than acutely.
If higher doses produce unexpected psychoactive effects, standard cannabinoid aftercare applies: adequate hydration, light nutrition, and rest. The experience should resolve within hours for inhaled administration. If anxiety or mood disturbance persists beyond 24 hours, consult a healthcare provider.
Recovery & Support
THCV does not produce physical dependence at characterized doses and lacks the reward-circuit activation associated with compulsive cannabis use. No THCV-specific recovery resources exist.
Individuals using THCV as part of broader cannabis consumption who wish to reduce or stop use can access general cannabis support resources. SAMHSA's National Helpline (1-800-662-4357) provides free, confidential referrals. Marijuana Anonymous and SMART Recovery offer peer support for cannabis-related concerns.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
No THCV-specific emergencies have been documented in the medical literature. At clinical doses, serious adverse reactions are not expected. If symptoms arise at higher doses, the most likely scenario is THC-like psychoactive distress.
Recognizing an emergency:
- Severe anxiety, panic, or paranoia that does not resolve with reassurance
- Chest pain, rapid heartbeat, or difficulty breathing
- Confusion, disorientation, or loss of consciousness
Immediate steps:
- 1. Move the person to a calm, quiet environment.
- 2. Reassure them that cannabinoid effects are temporary and will resolve.
- 3. If symptoms are severe (chest pain, breathing difficulty, loss of consciousness), call emergency services immediately.
- 4. Do not leave the person alone until symptoms have fully resolved.
What to tell the dispatcher: State the substance taken (THCV or cannabis product containing THCV), the amount and time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
THCV occupies a fragmented legal landscape that varies by jurisdiction and by the source material from which it is derived. It is not scheduled under the UN Convention on Psychotropic Substances (1971), leaving regulation to individual nations.[29] The core regulatory distinction in most jurisdictions is whether THCV derives from hemp (low-THC Cannabis sativa) or from marijuana (high-THC cannabis), as the source plant's THC content determines legality in several frameworks.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Not explicitly scheduled | Hemp-derived THCV (from plants with ≤ 0.3% Δ9-THC) is federally legal under the 2018 Agriculture Improvement Act (Farm Bill). Marijuana-derived THCV remains Schedule I as a cannabis extract. State laws vary significantly.[30] |
| United Kingdom | Class B, Schedule 1 | Illegal to possess, supply, or produce without a Home Office license. GW Pharmaceuticals conducted Phase 2 trials under regulatory authorization.[30] |
| European Union | Not explicitly scheduled | Not listed in most national controlled substance schedules beyond cannabis. Hemp-derived THCV (from plants with less than 0.2% THC) occupies uncertain legal status in most member states.[29] |
| Canada | Regulated under the Cannabis Act (2018) | Legal for medical and recreational use when purchased from licensed retailers.[29] |
| Australia | Presumed controlled | Specific scheduling not confirmed. As a cannabis-derived compound, THCV likely falls under TGA cannabis regulations.citation needed |
| International (UN) | Not scheduled | Not listed under the UN Convention on Psychotropic Substances (1971) or the Single Convention on Narcotic Drugs (1961).[29] |
Detection and drug testing
THCV is detectable in cannabis products via HPLC and gas chromatography-mass spectrometry. Standard urine drug screens primarily target THC metabolites; whether they cross-react with THCV metabolites has not been characterized.citation needed
references
- [1]
- [2]
- [3] ^abcdefghJadoon KA, Ratcliffe SH, Barrett DA, Thomas EL, Stott C, Bell JD, O'Sullivan SE, Tan GD (2016) Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study — Diabetes Care doi:10.2337/dc16-0650
- [4]
- [5] ^abcdThomas A, Stevenson LA, Wease KN, Price MR, Baillie G, Ross RA, Pertwee RG (2005) Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist — British Journal of Pharmacology PMID:16205722
- [6] ^abSmith GL (2025) Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin (THCV)-Infused Mucoadhesive Strips — Cannabis doi:10.26828/cannabis/2024/000206